glp-1 and gip Science Behind GLP 1 Glucagon Receptor Agonists for Obesity Research | News & Announcements Triple GLP-1 / GIP /

FDA approved orforglipron in 50 days

Originally developed and positioned as treatments for type 2 diabetes, these agents are now equally associated with weight management, reshaping how clinicians, patients, and pharmacies understand metabolic disease

The platform, called LillyDirect, joins a growing field of websites offering telehealth prescriptions for weight loss drugs.

HIGHLIGHTS: Grab-and-go stick packs

Results show broad benefits with a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions

Switching to the oral small molecule glucagon-like peptide-1 (GLP-1) orforglipron after taking injectable GLP-1s helped patients maintain mostbut not allof their weight loss, according to a clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.